GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-French health body approves AstraZeneca COVID-19 vaccine

Tue, 02nd Feb 2021 16:53

* Recommends use for those only aged under 65

* Decision makes AZ's vaccine third shot available in the
country
(Adds quote, details)

By Sudip Kar-Gupta and Geert De Clercq

PARIS, Feb 2 (Reuters) - France's top health advisory body
on Tuesday approved the use of AstraZeneca's COVID-19
vaccine, but said the shot should only be administered to those
aged under 65.

The Haute Autorite de la Sante (HAS) said people aged 50 to
65 with health issues and medical staff should get priority
access.

The decision makes AstraZeneca's vaccine the third shot
available in France, after those of Pfizer/BioNTech
and Moderna.

Its recommended use for those aged below 65 echoes similar
advice from experts in Italy, Austria, and Germany, which said
the vaccine should not be given to the elderly, citing a lack of
sufficient data to recommend use in older age groups.

"There is still insufficient data for those aged 65+. We
hope to have them in the coming weeks," the head of the HAS,
Dominique Le Guludec, told reporters.

"The vaccine's performance is satisfactory with a 62%-70%
efficacy depending on various study outcomes", she added.

The European Medicines Agency (EMA) gave the green light to
the AstraZeneca vaccine four days ago, saying there was not yet
enough results for people over the age of 55 to determine how
well the vaccine worked in that group but that it could still be
given to older people.

The approval is expected to ease pressure on the French
government, whose vaccination rollout strategy has been heavily
criticized for being too slow.

As of Feb. 1, more than 1.6 million doses had been
administered in France. That compares with an estimate of nearly
10 million in Britain.

But the European Union, which last year agreed to buy up to
400 million doses of the vaccine for the bloc, is at the centre
of a dispute with AstraZeneca over the speed of supplies.

Last week, the company unexpectedly announced cuts of up to
60% in supplies to European countries, citing production
problems at a Belgian factory and triggering a furious response
from Brussels.

The HAS said it expected France to get 10 million doses of
the AstraZeneca vaccine in the next three months, which would
allow 5 million people to get vaccinated, given its two-dose
regimen.

In the same timeframe, France hopes to secure 19.3 million
shots from Pfizer/BioNTech and 3 million from Moderna.

French European Affairs Minister Clement Beaune said on
Monday he expected first doses of the AstraZeneca vaccine to
arrive by next week at the latest.

(Reporting by Sudip Kar-Gupta, Geert De Clercq; Writing by
Matthias Blamont; Editing by Bernadette Baum and Rosalba
O'Brien)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.